12.07.2015 Views

Overview and Introduction - BEBAC • Consultancy Services for ...

Overview and Introduction - BEBAC • Consultancy Services for ...

Overview and Introduction - BEBAC • Consultancy Services for ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

1/6 | <strong>Overview</strong> & <strong>Introduction</strong>Dobrodošli!Design <strong>and</strong> Evaluationof BE StudiesHelmut Schütz<strong>BEBAC</strong><strong>Consultancy</strong> <strong>Services</strong> <strong>for</strong>Bioequivalence <strong>and</strong> Bioavailability Studies1070 Vienna, Austriahelmut.schuetz@bebac.atin<strong>for</strong>malife sciencesBioequivalence <strong>and</strong> Bioavailability, Pre-Conference Workshop | Ljubljana, 17 May 2010 1 • 10


1/6 | <strong>Overview</strong> & <strong>Introduction</strong>Answering the Question:What is Enlightenment?in<strong>for</strong>malife sciences„Enlightenment is man’s emergencefrom his self-imposed immaturity <strong>for</strong>which he himself was responsible.Immaturity <strong>and</strong> dependence are theinability to use one’s own intellectwithout the direction of another. Oneis responsible <strong>for</strong> this immaturity <strong>and</strong>dependence, if its cause is not a lackof intelligence, but a lack of determination <strong>and</strong> courage tothink without the direction of another. Sapere aude!Have courage to use your own underst<strong>and</strong>ing! is there<strong>for</strong>ethe slogan of Enlightenment.” Immanuel Kant (1784)Bioequivalence <strong>and</strong> Bioavailability, Pre-Conference Workshop | Ljubljana, 17 May 2010 2 • 10


1/6 | <strong>Overview</strong> & <strong>Introduction</strong>To bear in Remembrance...Whenever a theory appears to youas the only possible one, take this asa sign that you have neither under-stood the theory nor the problemwhich it was intended to solve.Even though it’s applied sciencewe’re dealin’ with, it still is – science!Karl R. PopperLeslie Z. Benetin<strong>for</strong>malife sciencesBioequivalence <strong>and</strong> Bioavailability, Pre-Conference Workshop | Ljubljana, 17 May 2010 3 • 10


1/6 | <strong>Overview</strong> & <strong>Introduction</strong>BioequivalenceMain TopicsSurrogate of clinical equivalence orMeasure of pharmaceutical quality?Types of studiesPharmacokinetic (PK)Pharmacodynamic (PD)Clinical (equivalence <strong>and</strong>/or safety/efficacy)in<strong>for</strong>malife sciencesBioequivalence <strong>and</strong> Bioavailability, Pre-Conference Workshop | Ljubljana, 17 May 2010 4 • 10


1/6 | <strong>Overview</strong> & <strong>Introduction</strong>Main TopicsTypes of studies (cont’d)Healthy SubjectsPatientsSingle doseMultiple doseCross-overParallelReference product (another modified release<strong>for</strong>mulation, IR, solution)in<strong>for</strong>malife sciencesBioequivalence <strong>and</strong> Bioavailability, Pre-Conference Workshop | Ljubljana, 17 May 2010 5 • 10


1/6 | <strong>Overview</strong> & <strong>Introduction</strong>Main Topicsin<strong>for</strong>malife sciencesTypes of studies (cont’d)(PK interaction)Food effectDesign IssuesDose regimenFasted / fed stateType of st<strong>and</strong>ard mealsBioanalytics (not GLP!)Parent drug / metabolite(s) / enatiomers / pro-drugsValidation / routine applicationBioequivalence <strong>and</strong> Bioavailability, Pre-Conference Workshop | Ljubljana, 17 May 2010 6 • 10


1/6 | <strong>Overview</strong> & <strong>Introduction</strong>Main TopicsEthics (GCP!)Dose levels / number of administered dosesNumber / volume of blood samplesDrug <strong>and</strong>/or adverse effectsClinical per<strong>for</strong>mance (GCP!)CRO selectionResponsibilities of sponsor / investigatorAudits / monitoringin<strong>for</strong>malife sciencesBioequivalence <strong>and</strong> Bioavailability, Pre-Conference Workshop | Ljubljana, 17 May 2010 7 • 10


1/6 | <strong>Overview</strong> & <strong>Introduction</strong>Main Topicsin<strong>for</strong>malife sciencesNCA / PK (PD)Sampling scheduleMetrics (AUC, C max ; AUEC, Ae max ,…)Design, methods, evaluationSample sizeEstimation from previous <strong>and</strong>/or pilot studies,literatureHighly variable drugsBiostatisticsModels & assumptionsProtocol, evaluation, reportBioequivalence <strong>and</strong> Bioavailability, Pre-Conference Workshop | Ljubljana, 17 May 2010 8 • 10


1/6 | <strong>Overview</strong> & <strong>Introduction</strong>‘What if’-scenariosCommon pitfallsMain TopicsProblems in clinical per<strong>for</strong>mance – studies ‘on hold’Failure to meet the required per<strong>for</strong>mance inbioanalyticsBlind review‘Failed’ studiesDeficiency lettersin<strong>for</strong>malife sciencesBioequivalence <strong>and</strong> Bioavailability, Pre-Conference Workshop | Ljubljana, 17 May 2010 9 • 10


1/6 | <strong>Overview</strong> & <strong>Introduction</strong>Another reminderin<strong>for</strong>malife sciencesRoseis a roseis a roseis a rose. Gertrude Stein (1913)Guidelinesare guidelinesare guidelines.Henrike Potthast (ca. 2004)In advanced engineering, you expected failure; you learnedas much from failures as from successes – indeed if younever suffered a failure you probably weren’t pushing theenvelope ambitiously enough.Stephen Baxter; Transcendent, Chapter 36 (2006)Bioequivalence <strong>and</strong> Bioavailability, Pre-Conference Workshop | Ljubljana, 17 May 2010 10 • 10

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!